1. Volume 4, Issue 9, Pages 673-684 (September 2017)
Neurofeedback, sham neurofeedback, and cognitive-behavioural group therapy in adults with attention-deficit hyperactivity disorder: a triple-blind, randomised, controlled trial 
Dr Michael Schönenberg, PhD, Eva Wiedemann, PhD, Alexander Schneidt, PhD, Jonathan Scheeff, MSc, Alexander Logemann, PhD, Philipp M Keune, PhD, Prof Martin Hautzinger, PhD 
The Lancet Psychiatry 
Volume 4, Issue 9, Pages (September 2017)
DOI: /S (17)
Copyright © 2017 Elsevier Ltd Terms and Conditions

2. Figure 1
Trial profile
ADHD=attention-deficit hyperactivity disorder. *Others included, for example, those who could not get possible scheduled appointments for the diagnostic interviews, or unexpected work-related or private issues that led to withdrawal from the study.
The Lancet Psychiatry 2017 4, DOI: ( /S (17) )
Copyright © 2017 Elsevier Ltd Terms and Conditions

3. Figure 2 Observed trajectories of CAARS, BDI-II, and STAI-state scores
Observed trajectories for (A–D) attention-deficit hyperactivity disorder symptoms, (E) depression, and (F) anxiety over the study period as a function of treatment condition. Errors bars are standard errors. CAARS=Conners' adult ADHD rating scale. BDI-II=Beck depression inventory-II. STAI-state=state subscale of the state trait anxiety inventory.
The Lancet Psychiatry 2017 4, DOI: ( /S (17) )
Copyright © 2017 Elsevier Ltd Terms and Conditions

4. Figure 3
Observed trajectories of electroencephalographic θ-to-β ratios
Observed trajectories are logarithmically transformed. Electroencephalographic θ-to-β ratios were measured in the eyes-closed condition at the vertex as a function of treatment condition. Errors bars are standard errors.
The Lancet Psychiatry 2017 4, DOI: ( /S (17) )
Copyright © 2017 Elsevier Ltd Terms and Conditions